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LipidAlthough coupled to Gi/o proteins, cannabinoid CB1 receptors can also activate intracellular Ca2+ ([Ca2+]i)
accumulation through not fully understood mechanisms. We report that in, human neuroblastoma SH-SY5Y
cells, CB1 activation with the speciﬁc agonist arachidonoylchloroethanolamide (ACEA), weakly elevates
[Ca2+]i and that this effect, when using low (1–100 nM) concentrations of ACEA, is enhanced by the previous
activation of Gq/11-coupled M3 muscarinic receptors with carbachol, dose-dependently and up to ∼8-fold. A
similar behaviour was also observed with carbachol and the Gi/o-coupled δ-opioid receptor. Furthermore,
stimulation of CB1 receptors produced a concentration-dependent leftward shift of the elevation of [Ca
2+]i by
δ-opioid receptors. These stimulatory effects were variedly attenuated by selective antagonists of each
receptor, pertussis toxin, inhibitors of phospholipase C (U73122 and D609), and, when assessed in the
presence of extracellular Ca2+, by the block of voltage-activated calcium channels. Cholera toxin only slightly
inhibited the Gq/11-Gi/o-mediated cross-talk, but induced a stronger inhibition of the Gi/o-Gi/o-mediated
interaction. These ﬁndings suggest that activation of M3 muscarinic receptors might produce a qualitative
alteration of the signaling associated with Gi/o-coupled receptors, and that sequential activation of CB1 and
δ-opioid receptors, both coupled to Gi/o, produces instead synergistic effects on [Ca2+]i elevation.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionCannabinoid type-1 (CB1) receptors are members of the super-
family of the G-protein-coupled receptors (GPCRs), with a structure
deﬁned by seven membrane-spanning helices, six intracellular loops
and an intracellular C-terminal domain that can associate with
G-proteins [1–2]. Cannabinoid receptors are usually associated with
proteins of the Gi/o family. Signal transduction via Gi inhibits adenylyl
cyclase in most tissues and cells, although coupling of the cannabinoid
CB1 receptor to Gs and subsequent stimulation of adenylyl cyclase has
also been reported [1,3]. Evidence exists for CB1-mediated Ca2+ ﬂuxes,
stimulation of phospholipases A2 and C, and regulation of K+ and Ca2+
ion channels, probably via Go [3–8]. Ion channel regulation represents
an important component of the neuromodulation exerted by
endogenous CB1 receptor ligands (endocannabinoids) released in
response to neuronal depolarization. Like CB1 receptors, opioidGroup, Istituto di Chimica
ampi Flegrei 34, Comprensorio
3; +39 0818675191; fax: +39
zo).
ll rights reserved.receptors are also seven-transmembrane-spanning and Gi/o protein-
coupled receptors, participating in a multitude of biological responses
[9]. Their activation stimulates intracellular signaling mechanisms
including activation of inwardly rectifying potassium channels, and
inhibition of both voltage-operated N-type Ca2+ channels and
adenylyl cyclase activity [10]. It is now clear that, like many other
Gi/o-coupled receptors, opioid receptor activation can signiﬁcantly
elevate free intracellular Ca2+ ([Ca2+]i), although the mechanism
underlying this phenomenon is not well understood [11,12]. In some
cases opioid receptor activation alone appears to elevate [Ca2+]i [13],
but in other cases this phenomenon requires the concomitant
activation of Gq/11-coupled receptors, which themselves stimulate
Ca2+ release from intracellular stores via the inositol–phosphate
pathway [14].
The SH-SY5Y human neuroblastoma cell line is widely employed for
the studyof the functional cross-talk betweenGPCRs and, particularly, of
the coincident signaling on the mobilization of [Ca2+]i induced by their
stimulation. In the present study, we have investigated if, as previously
shown for δ-opioid receptors [15–17], the signaling of CB1 receptors at
[Ca2+]i can be enhanced by previous stimulation of Gq/11-coupled
receptors, such as the M3 muscarinic receptors, and if, moreover, this
signaling can inﬂuence another Gi/o-coupled receptor, i.e. the δ-opioid
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synergistic functional interactions between these two receptor types
[18]. For this purpose, and also in order to investigate the mechanisms
of these putative interactions, we have carried out measurements of
[Ca2+]i in SH-SY5Y cells in the presence of several selective pharmaco-
logical tools targeting intracellular signaling molecules, and in the
presence and absence of extracellular Ca2+.
2. Materials and methods
2.1. Cell cultures
Human neuroblastoma SH-SY5Y cells (passage 10–40) were grown
asmonolayers in DMEM (Sigma-Aldrich, St. Louis, Mo, USA) according
to the instructions of the manufacturer, supplemented with 20% fetal
bovine serum, 1 mM sodium pyruvate, 10 mM HEPES, 100 IU/ml
penicillin and 100 μg/ml streptomycin and maintained under 95%–5%
O2/CO2 at 37 °C.
2.2. Immunoﬂuorescence studies
For immunoreaction studies, SH-SY5Y cells were seeded on sterile
coverslips (22×22 mm, Menzel, Germany) in 6-well culture plates
and incubated under standard conditions until they were 50–70%
conﬂuent. Cultured cells were processed for immunoﬂuorescence.
After threewasheswith PBS, cells were ﬁxed by incubation in 4% (v/v)
paraformaldehyde in PBS for 20min at room temperature, rinsed with
PBS, permeabilized for 15 min with 0.5% Triton X-100 in PBS and
incubated overnight at 4 °C. For double immunoﬂuorescence, SH-SY5Y
human neuroblastoma cells were incubated for 1 h in 10% normal
donkey serum (NDS, Jackson Immunoresearch Laboratories, West
Grove, PA) in PB containing 0.3% Triton X-100 (block solution). The
cells were incubated overnight at 4 °C in a humid chamber with the
respective polyclonal antibodies (all diluted in block solution).Fig. 1. Immunostaining of human SH-SY5Y neuroblastoma cells for M3, CB1 and δ-opioid r
SH-SY5Y human neuroblastoma cells as determined by M3 (a and d), CB1 (b and g) and δ-op
and CB1 and M3 and δ-opioid receptors in the cytoplasm and neuronal processes. The arro
process. Scale bar: 25 μm.Subsequently, the cells were processed for three different double
immunoﬂuorescence as follows: goat polyclonal anti-M3 receptor
immunoreaction (1:200, Santa Cruz Biotechnology, Santa Cruz, CA
USA) alternatively coupled with rabbit polyclonal anti-CB1 receptor
(1:400, Calbiochem, Merck Chemicals Ltd, Nottingham, UK) or rabbit
polyclonal anti δ-opioid receptor (1:200, Santa Cruz Biotechnology);
goat polyclonal anti-CB1 receptor coupled to rabbit polyclonal anti
δ-opioid receptor (both diluted 1:200, Santa Cruz Biotechnology).
After threewashes in PB, double immunoﬂuorescencewas revealed by
incubation for 2 h in the appropriate ﬂuorochrome conjugated secon-
dary antibody: Alexa Fluor488 donkey anti-goat (Molecular Probes/
Invitrogen, UK Paisley, UK) (for M3 and CB1 receptors); Alexa Fluor546
donkey anti-rabbit (Molecular Probes/Invitrogen) (for CB1 and
δ-opioid receptors) all diluted 1:100 in NDS block solution. Thereafter,
cells were washed with PB and coverslipped with Aquatex mounting
medium (Merck, Darmstadt, Germany). Cells processed for immuno-
ﬂuorescence were studied with an epiﬂuorescence microscope
equipped with the appropriate ﬁlter and, then, acquired using a
digital camera (Leica DFC 320) connected to the microscope and
image analysis software (Leica IM500). Settings for excitation of
ﬂuorescein isothiocyanate (488 nm) and Texas Red (543 nm) were
identical throughout the analysis. Digital images were processed in
Adobe Photoshop, with brightness and contrast being the only
adjustments made. Controls included omission of either the primary
antisera or the secondary antibodies. These control experiments did
not show staining.
2.3. Western immunoblotting
Human SH-SY5y neuroblastoma cells were lysed in 1 ml of lysis
buffer (50 mM Tris–HCl, pH 7.5, 100 mM NaCl, 5 mM EDTA, 0.25 M
sucrose, HEPES 10 mM, MgCl2 1 mM, 1% Triton X-100, 100 μg/ml
phenylmethylsulfonyl ﬂuoride, 4 μg/ml aprotinin, and 0.7 μg/ml
pepstatin) and then centrifuged at 800 g for 10 min. The supernatanteceptors. Photomicrographs showing localization of M3, CB1 and δ-opioid receptors in
ioid (e and h) immunoﬂuorescence. Note the nearly complete overlapping between M3
w in g–i shows a CB1 immunopositive (g) but δ-opioid immunonegative (h) neuronal
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buffer (50 mM Tris–HCl, pH 7.5, 100 mM NaCl, 5 mM EDTA, 0.25 M
sucrose, 1% Triton X-100, 1 mM dithiothreitol, 100 μg/ml phenyl-
methylsulfonyl ﬂuoride, 4 μg/ml aprotinin, and 0.7 μg/ml pepstatin)
and then collected by centrifugation at 10,000 g for 20 min. Protein
concentration was determined by the BCA Protein Assay kit (BioRad
Laboratories, Segrate, Milan, Italy) using bovine serum albumin as aFig. 2. Representative traces showing typical Ca2+ transients induced in SH-SY5Ycells byconsec
coupled receptor consecutive stimulation. Typical Fura 2-AMtraces obtainedwith cells stimulate
bradykinin10 μMconsecutivelyare shown.Arrows showthe timeof additionof the compounds t
2AMtracesof cells stimulatedwith CB1 selectiveagonistACEA10nMalone,with CCh1 μMandA
(1 μM) and ACEA (10 nM). Arrows show the time of addition to the quartz cuvette of the compo
cells stimulated with the δ-opioid selective agonist DPDPE (100 nM) alone, or in presence of C
antagonist naltrindole (1 μM). Arrows show the time of addition to the quartz cuvette of th
representative of several separate experiments.standard. Concentrations of total proteins were determined from the
absorption spectrum measured at A562. Samples for western blotting
(15 μL) were separated by 7.5% SDS-polyacrylamide gel electropho-
resis using the BioRad minigel system. Proteins were electro-
transferred to PVDF membrane using the BioRad semi-dry blotter
apparatus according to manufacturer's instructions. Following elec-
tro-transfer, the membranes were blocked for non-speciﬁc bindingutive stimulationofGq/11–Gq/11, Gq/11–Gi/o andGi/o–Gi/o-coupled receptors. (a)Gq/11–Gq/11
dwith CCh 1mMandbradykinin 10 μMalone andwith cells stimulatedwith CCh1 μMand
o thequartz cuvette. (b)Gq/11–Gi/o-coupled receptorconsecutive stimulation. Typical Fura-
CEA10nMconsecutivelyandwith the selective CB1 receptorantagonist AM251 (1 μM),CCh
unds. (c) Gi/o–Gi/o-coupled receptor consecutive stimulation. Typical Fura-2-AM traces of
B1 receptor pre-stimulation with ACEA (10 nM), and in presence of the selective δ-opioid
e compounds. These experiments were carried out in a Ca2+-containing buffer and are
Table 1
Summary of the EC50 values for the effects of M3 muscarinic, BK2, CB1 and δ-opioid receptor agonists on cytosolic Ca2+ elevation.
Substance + Ca
2+
−Ca2+ EC50 −Log EC50 Efﬁcacy (% maximal response to CCh 1 mM)
Carbachol 1.52±0.46 μM 5.82±0.15 100.00±7.05
0.42±0.14 μM 6.37±0.18 100.00±7.93
Acetylcholine 1.36±0.43 μM 5.86±0.16 94.36±4.22
0.31±0.13 μM 6.51±0.23 80.20±4.01
Bradykinin 26.60±4.61 nM 7.57±0.07 46.47±2.82
48.91±14.95 nM 7.31±0.16 48.12±4.01
ACEA 43.51±11.64 nM 7.36±0.13 22.53±1.41
105.11±23.27 nM 6.98±0.10 32.08±4.21
WIN 55,212-2 75.43±29.43 nM 7.12±0.20 18.31±1.48
45.06±19.26 nM 7.35±0.22 32.08±8.02
HU210 70.56±49.66 nM 7.15±0.52 18.13±2.01
97.63±36.63 nM 7.01±0.20 24.06±4.01
DPDPE 71.20±20.25 nM 7.15±0.14 12.68±2.01
48.80±16.80 nM 7.31±0.18 16.04±3.21
The EC50 values for the cytosolic Ca2+ elevation by Gq/11-coupled receptor stimulation, by the muscarinic receptor non-selective agonists CCh and Ach, and the BK2 receptor agonist,
bradykinin, and for the Gi/o-coupled receptor stimulation, the CB1 receptor agonists ACEA,WIN55,212 and HU210, and the δ-opioid receptor agonist, DPDPE, are shown. The efﬁcacies
(Emax) are expressed as percent of the maximum effect obtained with 1 mM CCh in either buffer solutions used.
Data are means of at least n=12 different determinations. EC50 (nM) and −Log EC50 values are reported.
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Tris/HCl, 150 mM NaCl, pH 7.6) containing 0.1% Tween-20 (TBS-T),
supplemented with 5% non-fat milk. After blocking, membranes were
washed in TBS-T, and incubated overnight at 4 °C with the appropiate
antibody, the rabbit polyclonal M3-speciﬁc antibody (Santa Cruz,
1:1000 dilution in 5% milk/TBS-T), the rabbit polyclonal anti-δ-opioidFig. 3. Cytosolic Ca2+ concentration in SH-SY5Y cells: effects of M3 muscarinic, BK2, CB1 and δ
agonist carbachol (CCh). (b and d) Dose–response curves of the BK2 receptor agonist, brad
experiments were performed in both Ca2+-containing and Ca2+-free buffer solutions. Data(Santa Cruz, 1:1000 in 5% milk/TBS-T), the goat polyclonal anti-CB1
antibody (Calbiochem, 1:1000 dilution in 5% milk/TBS-T) for three
different membranes respectively. Primary antibodies were detected
for 1 h at room temperature with a secondary antibody (goat anti-
rabbit; 1:3000 dilution in 5%milk/TBS-T forM3 and δ-opioid receptors
and rabbit anti-goat, 1:3000 dilution in 5% milk/TBS-T for CB1-opioid receptor stimulation. (a and c) Dose–response curves of the muscarinic receptor
ykinin, the CB1 receptor agonist, ACEA, and the δ-opioid receptor agonist, DPDPE. All
are means±S.E. of a least n=12 measurements.
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chemiluminescence detection using the BioRad Immunostar™ AP
chemiluminescent protein detection system and exposure to Kodak
Biomax Light Film for chemiluminescence. The detection of the mole-
cular weight was performed used Precision protein™ streptactin-AP
conjugate (BioRad Laboratories, Italy).
2.4. Pharmacological tools
Fura-2-AM, was from Molecular Probes/Invitrogen (Inchinnan
Business Park, Paisley, UK). HU-210 and arachidonoylchloroethanola-
mide (ACEA), were from Tocris Bioscience (Avon Mouth, Bristol, UK).
U73122, AM251, phorbol 12,13-dibutyrate (PDbU), 4α-phorbol
12,13-dibutyrate (4α-PDbU), bisindolymaleimide (BIM) and thapsi-
garginwere purchased from Alexis Biochemicals (San Diego, CA, USA).
WIN55,212-2, [D-Pen(2,5)]-enkephalin (DPDPE), acetylcholine, car-
bachol, atropine, D609, nifedipine, 4-DAMP, naltrindole, lanthanum
chloride, bradykinin acetate salt, phenylmethylsulfonyl ﬂuoride
(PMSF), aprotinin, pepstatin, pertussis toxin (PTX) and cholera toxin
(CTX) were obtained from Sigma-Aldrich (St. Louis, MO, USA). The
inhibitors of 2-arachidonoylglycerol (2-AG) biosynthesis via diacyl-
glycerol lipase (DAGL) enzymes, THL and OMDM188, and the inhibitor
of 2-AG degradation via the monoacylglycerol lipase (MAGL),
OMDM169, were synthesised as described previously [19] and kindly
provided by Prof. G. Ortar, from the University of Rome “La Sapienza”.Fig. 4. Effects of M3 muscarinic and CB1 antagonists and of the PLCβ inhibitor U73122 on c
response curves of the inhibition by the M3 muscarinic non-selective antagonist atropine, th
using a ﬁxed dose of CCh (1 μM). (b and d) Dose–response curves of the effect of ACEA, teste
performed in both Ca2+-containing and Ca2+-free buffer solutions. Data are means±S.E. o2.5. Measurements of [Ca2+]i induced by muscarinic, CB1 and δ-opioid
receptors in SH-SY5Y cells
The effect of the various compounds on [Ca2+]i was determined
by using Fura-2AM, a selective intracellular ﬂuorescent probe for
Ca2+. The dye was excited at 340 and 380 nm to monitor relative
[Ca2+]i changes by the F340/380 ratio, and the emission was at
540 nm. Changes in ﬂuorescence were monitored after a 5 min
stabilization period, in a 0–300 s time interval after cell stimulation.
On the day of the experiment, cells were loaded for 1 h at 25 °C with
2.5 μM Fura-2AM dissolved in dimethyl sulfoxide (DMSO), sus-
pended in DMEM medium without fetal bovine serum. After the
loading step, cells were washed with two differents buffer solutions,
a Ca2+-containing buffer (pH 7.4, 145 mM NaCl, 2.5 mM KCl, 1.5 mM
CaCl2, 1.2 mM MgCl2, 10 mM HEPES, 25 mM glucose) to monitor
changes in [Ca2+]i in the presence of extracellular calcium, and a
Ca2+-free buffer (pH 7.4, 145 mM NaCl, 2.5 mM KCl, 2.7 mM, MgCl2,
10 mM HEPES, 25 mM glucose, EGTA 0.1 M), to monitor changes in
[Ca2+]i in the absence of extracellular calcium. Cells were then
resuspended in appropriate buffer and transferred (2 mL) to a quartz
cuvette for ﬂuorescence detection (Perkin-Elmer LS50B) under
continuous stirring. The efﬁcacy of the agonists was determined by
comparing it to the maximal effect on [Ca2+]i observed with 1 mM
carbachol with Ca2+-containing or Ca2+-free buffers. Dose–response
curves were always constructed using different aliquots of cells fromarbachol and ACEA-induced cytosolic Ca2+ elevation in SH-SY5Y cells. (a and c) Dose–
e M3 muscarinic selective antagonist 4-DAMP and the PLCβ inhibitor U73122, calculated
d using a ﬁxed dose of the selective CB1 antagonist AM251 (1 μM). All experiments were
f a least n=12 measurements.
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compounds to the same cells. In the case of antagonist studies, the
antagonist was administered 300 s before the agonist at the same
cell aliquots, and the experiment time course was monitored. The
effects of the solvents used (DMSO or methanol, maximum 0.2% v/v),
monitored for the same time course, was considered as blank, and
subtracted from the ﬁnal values. Both EC50 and IC50 were calculated
by using GraphPad®, and are reported as means±SEM of at least
n=12 experiments.
2.6. Cell treatments for studies on receptor interactions
We tested the effects on [Ca2+]i following the consecutive
stimulation of two receptors. After an equilibration period of 300 s,
the cells were ﬁrst stimulated with one agonist (either carbachol, forFig. 5. Gq/11 and Gi/o-coupled receptor cytosolic Ca2+ elevation: pharmacological characteri
(atropine [Atro] and 4-DAMP respectively), selective antagonists of CB1 and δ-receptors (AM
channel blockers (lanthanum chloride [La3+] and nifedipine [Nife]), SERCA inhibitor (thaps
CB1 (ACEA) and δ-opioid (DPDPE) receptor stimulation on cytosolic Ca2+, tested in Ca2+-c
obtained for each agonist alone at the dose indicated, and are means±S.E. of at least n=1
#pb0.05 vs Ctrl ACEA 100 nM One Way ANOVA, followed by Dunn's test. §pb0.05 vs Ctrl DPmuscarinic receptors, or ACEA, for the CB1 receptor) and, after 300 s,
with another agonist (either the BK2 receptor agonist, bradykinin,
after CCh, or the CB1 receptor agonist, ACEA, after CCh, or the δ-opioid
receptor agonist, DPDPE, after ACEA or CCh). Different doses of each
agonist were used. The EC50 and IC50 values were calculated in both
Ca2+-containing and Ca2+-free buffers by using GraphPad®, and are
reported as means±SEM of at least n=6 experiments.
2.7. Pharmacological characterization of the effects on [Ca2+]i
Once that the EC50 values of the selective agonists of Gq/11- and Gi/o-
coupled receptors, given to cells alone or in combination, were
established, the effects of: a) selective receptor antagonists, b) phospho-
lipase C (PLC) inhibitors, c) calcium channel blockers, d) thapsigargin,
and e) in the case of the experiments on Gq/11–Gi/o and Gi/o–Gi/ozation. The effects of non-selective and selective antagonists of M3 muscarinic receptor
251 and naltrindole [Naltri], respectively), PLC inhibitors (U73122 and D609), calcium
igargin [Thaps]) and PTX and CTX (500 ng/mL, 24 h) on the effect of muscarinic (CCh),
ontaining and Ca2+-free buffers are shown. Data are reported as percent of the effects
2 determinations. ⁎pb0.05 vs Ctrl CCh 1 μM One Way ANOVA, followed by Dunn's test.
DPE 100 nM One Way ANOVA, followed by Dunn's test.
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dibutyrate (PDbU), the inactive analogue 4α-phorbol 12,13-dibutyrate
(4α-PDbU) and the PKC inhibitor, bisindolymaleimide (BIM), and the
inhibitors of 2-AG biosynthesis (THL, OMDM-188) and degradation
(OMDM-169) were tested. The drugs were given 5 min before
receptor stimulation. The data were expressed as percent of maximal
response obtained with a control dose of agonist. The effects of both
PTX and CTX were assessed, instead, after 24 h incubation of cells with
500 ng/mL of the toxin dissolved in the medium. At the day of the
experiment, the various selective agonists were then tested and their
effects compared with those obtained in cells incubated for 24 h with
medium. All experiments were carried out using both types of buffer
solutions.
3. Results
3.1. Human SH-SY5Y neuroblastoma cells express M3, CB1 and
δ-opioid receptors
The expression of the M3 muscarinic, δ-opioid and CB1 receptors
was revealed by immunoﬂuorescence in SH-SY5Y neuroblastoma
cells by means of antibodies selective for M3 (Fig. 1a and d), CB1
(Fig. 1b and g) and δ-opioid receptors (Fig. 1e and h). Each single
immunostaining revealed speciﬁc dot-like signals. M3R/CB1 R and
M3R/δ-opioid R double immunoﬂuorescence showed a complete
overlapping of the signal in the cytosol, plasma membrane andFig. 6. Consecutive stimulation of Gq/11-coupled receptors: effect on cytosolic Ca2+ elevation.
stimulation ofM3muscarinic receptors with various concentrations of CCh, in either buffer so
bradykinin, in either buffer solution. Data are expressed as percent of the maximum effect oneuronal processes (Fig. 1c and f, respectively). On the other hand
CB1 R/δ-opioid R signals were not completely overlapping in the
neuronal processes of SH-SY5Y neuroblastoma cells (see arrow in
Fig. 1g–i).
3.2. Western blot analysis of M3, CB1, δ-opioid-speciﬁc antibodies
A series of blots were prepared each containing same amount of
lysates (115 μg) from human SH-SY5Y neuroblastoma cells, and for
each type of receptor investigated (Fig. 1, Supplementary materials).
For western blotting analysis of M3 receptors, the antibody revealed a
band at approximately ∼75 kDa, whereas for the δ-opioid receptors
the antibody revealed a band at approximately ∼58 kDa. The CB1
primary antibody detected a major CB1 species of ∼60 kDa. These
bands represent monomeric more or less glycosylated forms, the size
of which has been reported previously in the literature.
3.3. Effects on [Ca2+]i induced by M3, BK2, CB1 and δ-opioid receptors
in human SH-SY5Y neuroblastoma cells
Human SH-SY5Y neuroblastoma cells express different types of
GPCRs. In the present study, we focused our attention in particular on
receptors coupled to αq/11 and αi/o subunits, such as the M3 mus-
carinic and bradykinin (BK2) (Gαq/11) receptors, and the CB1 and
δ-opioid (Gαi/o) receptors, with the aim to investigate their possible
involvement in intracellular Ca2+ mobilization, well established for(a and c) Dose–response curves of the effect of bradykinin obtained 300 s following pre-
lutions. (b and d) Dose–response curves of the effect of CCh on various concentrations of
btained with CCh 1 mM and are means±S.E. of at least n=6 different determinations.
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shown in Fig. 2a, carbachol (CCh) (a non-selective ligand for mus-
carinic receptors) and bradykinin (a selective BK2 receptor agonist)
induced a dose-dependent intracellular calcium transient, observed
for up to 150 s from cell treatment and also in absence of
extracellular calcium. CCh was the most potent drug at elevating
[Ca2+]i with EC50 values equal to 1.52±0.45 μM (−Log EC50: 5.82±
0.15) and 0.42± 0.14 μM (−Log EC50: 6.37±0.18), using Ca2+-
containing and Ca2+-free buffers, respectively (Table 1, Fig. 3a and c).
Therefore, the F340/380 values obtained with the maximal dose of
CCh (1 mM) were used as the maximal responses in either
experimental conditions (the F340/380 ratio was 1.512±0.021 in the
Ca2+-containing buffer and 0.517± 0.011 in the Ca2+-free buffer). In
the presence of 10 μM mecamylamine, a nicotinic antagonist,
administered 5 min before CCh, the amplitude of F340/380 ratio in
both buffer conditions was not affected (data not shown). The EC50
values for CCh, ACh and bradykinin are shown in Table 1. The non-
selective muscarinic receptor antagonist, atropine inhibited in a
dose-dependent manner the effect of CCh (1 μM) with IC50 values of
112.62±34.30 nM (−Log IC50: 6.92±0.14) and 15.04±6.10 nM
(−Log EC50: 7.81±0.22) in the Ca2+-containing or Ca2+-free
buffers, respectively. The selective M3 muscarinic receptor agonist,
4-DAMP was more potent than atropine at inhibiting the CCh (1 μM)
effect with IC50 values of 1.51±0.29 nM (−Log IC50: −8.82±0.09)
in the Ca2+-containing buffer, and 29.06±7.21 nM (−Log IC50:
−7.53±0.12) in the Ca2+-free buffer (Fig. 4a and c). 4-DAMP at
10 nM signiﬁcantly antagonized the effect of CCh with a right-ward
shift of the dose–response curve and a subsequent decrease of the
M3-mediated elevation of [Ca2+] with Ki of 25.85± 12.62 μM in the
Ca2+-containing buffer and 3.84±2.33 μM in the Ca2+-free buffer
(data not shown).Table 2
Summary of the effects of muscarinic receptor pre-stimulation on the BK2, δ-opioid and C
stimulation on δ-opioid receptor-induced stimulation of cytosolic Ca2+ elevation.
a) CCh inhibitory effect (Gq/11–Gq/11 interaction) + Ca
2+
−Ca2+
Bradykinin IC 50 (nM) −Log IC50
10 μM 50.41±14.40 7.30±0.14
5.60±1.60 8.22±0.13
1 μM 44.47±9.47 7.35±0.10
5.11±2.11 8.29±0.12
100 nM 18.28±5.28 7.74±0.15
5.04±2.04 8.30±0.11
10 nM 0.76±0.32 9.12±0.24
1.68±0.68 8.77±0.12
1 nM 0.03±0.03 10.49±0.95
0.12±0.01 9.91±0.06
1 pM N.D. N.D.
N.D. N.D.
c) CCh potentiating effect (Gq/11–Gi/o interaction) + Ca
2+
−Ca2+
ACEA EC50 (nM) −Log EC50
100 pM 0.98±0.26 9.00±0.13
0.45±0.40 9.35±0.96
1 nM 1.65±0.65 8.78±0.19
0.42±0.11 9.38±0.14
10 nM 1.61±0.63 8.79±0.21
0.43±0.16 9.36±0.20
100 nM 2.69±1.70 8.57±0.43
0.33±0.22 9.48±0.46
1 μM N.D. N.D.
N.D. N.D.
10 μM N.D. N.D.
N.D. N.D.
a) Inhibition by CCh of BK2 receptor-induced stimulation of cytosolic Ca2+ elevation.
b) Potentiation by CCh of δ-opioid receptor (DPDPE)-induced stimulation of cytosolic Ca2+
c) Potentiation by CCh of CB1 receptor (ACEA)-induced stimulation of cytosolic Ca2+ elevat
d) Potentiation by CB1 receptor pre-stimulation (with ACEA) of δ-opioid receptor (DPDPE)-
All experiments have been performed in both Ca2+-containing and Ca2+-free buffers and da
are reported.U73122, a PLCβ inhibitor, was also able to inhibit the CCh (1 μM)-
induced calciummobilizationwith a similar potency in Ca2+-containing
(IC50: 103.22±31.07 nM) (−Log IC50: 6.98±0.15) and Ca2+-free (IC50:
244.22±48.25 nM) (−Log IC50: 6.61±0.09) buffers (Fig. 4a and c).
In addition, in order to assess the effect of the stimulation of CB1
receptors on [Ca2+]i, WIN-55212-2, HU-210 and the CB1-selective
agonist ACEA were tested. As shown in Figs. 2b, 3b and d, and Table 1,
all CB1 agonists were able to induce a dose-dependent transient-like
elevation of intracellular Ca2+. In particular, in the Ca2+-containing
buffer, ACEA showed the highest efﬁcacy and potency (EC50: 43.51±
11.64 nM and −Log EC50: 7.36±0.13) at elevating [Ca2+]i, while
WIN-55212-2 and HU210 showed similar potencies and efﬁcacies. In
the Ca2+-free buffer, ACEA was again the drug with the highest
potency and efﬁcacy, while HU210 and WIN-55212-2 showed again
similar effects. In addition, in order to demonstrate the involvement of
CB1 receptors in these effects, a selective CB1 receptor antagonist,
AM251, was used. As shown in Fig. 4b and d, using both buffers,
AM251 at 1 μM signiﬁcantly antagonized the effect of ACEA, with a
right-ward shift of the dose–response curve and a subsequent de-
crease of the CB1-mediated elevation of [Ca2+]i (Ki=43.18±4.17 nM
for the Ca2+-containing buffer and Ki=179.7±4.9 nM for the Ca2+-
free buffer). Finally, we investigated the effect of δ-opioid receptor
stimulation on [Ca2+]i. DPDPE, a selective δ-opioid receptor agonist,
similar to CB1 agonists, was able to elevate [Ca2+]i with EC50 values of
71.20±20.25 nM (−Log EC50= 7.15±0.14) in the Ca2+-containing
buffer, and 48.80±16.80 nM (−Log EC50: 7.31±0.18) in the Ca2+-
free buffer (Fig. 3b and d, Table 1). The selective δ-opioid receptor
antagonist, naltrindole (Naltri), at a 1 μM concentration, was able to
inhibit, in both buffers, the effect of DPDPE with a Ki of 142.56±
13.31 nM for the Ca2+containing buffer and Ki: 87.12±46.21 nM for
the Ca2+-free buffer (data not shown).B1 receptor-induced stimulation of cytosolic Ca2+ elevation and of CB1 receptor pre-
b) CCh potentiating effect (Gq/11–Gi/o interaction) + Ca
2+
−Ca2+
DPDPE EC 50 (nM) −Log EC50
100 pM 1.07±0.40 8.71±0.18
3.39±1.39 8.47±0.78
1 nM 1.71±0.78 8.78±0.26
6.30±3.30 8.20±0.21
101 nM 2.32±1.32 8.63±0.29
2.57±1.57 8.60±0.24
100 nM 4.37±3.37 8.36±0.40
12.34±8.30 7.91±0.40
1 μM N.D. N.D.
N.D. N.D.
10 μM N.D. N.D.
N.D. N.D.
d) ACEA potentiating effect (Gi/o–Gi/o interaction) + Ca
2+
−Ca2+
DPDPE EC50 (nM) −Log EC50
10 μM 0.75±0.36 9.12±0.29
3.02±2.02 8.52±0.24
1 μM 1.37±0.52 8.86±0.21
4.54±3.54 8.34±0.41
100 nM 1.39±0.39 8.86±0.12
5.59±2.59 8.25±0.24
10 nM 1.48±0.58 8.83±0.22
2.38±1.38 8.62±0.25
1 nM 1.86±0.97 8.73±0.32
1.16±0.71 8.94±0.41
1 pM N.D. N.D.
N.D. N.D.
elevation.
ion.
induced stimulation of cytosolic Ca2+ elevation.
ta are means of at least n=6 different determinations. EC50 (nM) and−Log EC50 values
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agonists on [Ca2+]i
The effects of PLCβ and phosphatidylcholine (PC)-speciﬁc-PLC
inhibitors, calcium channel blockers, the SERCA (Sarco/Endoplasmic
Reticulum Ca2+-ATPase) inhibitor thapsigargin, and PTX and CTX
were tested on the effect of each single agonist on [Ca2+]i. The results
of these experiments, together with the effects of receptor antagonists
as a comparison, are shown in Fig. 5. The agonists were tested at
concentrations close to their EC50 values in either Ca2+-containing or
Ca2+-free buffers. As mentioned above, the PLCβ inhibitor, U73122, at
a 1 μM concentration, inhibited the CCh-mediated effect in both
experimental conditions. The PC-PLC inhibitor, D609, at a 40 μM
concentration, showed an effect only in the Ca2+-containing buffer.
Instead, thapsigargin (Thps, 1 μM), affected the CCh-mediated effect
only in the Ca2+-free buffer. No effect on the CCh-mediated elevation
of [Ca2+]i was observed with either PTX or CTX, nor with the calcium
channel blockers lanthanum chloride (La3+, 1 μM) and nifedipine
(Nife, 1 μM), in both experimental conditions. As mentioned above,
AM251 (1 μM) and naltrindole (Naltri, 1 μM) abolished the effects of
ACEA and DPDPE, respectively. No inhibition of the effects of these two
agonists on [Ca2+]i was observed with U73122, D609, Thps, La3+ and
Nife. On the other hand, cells incubated before the experiment with
PTX (500 ng/mL), but not with CTX (500 ng/mL), responded
signiﬁcantly less to the two agonists in both experimental conditions,Fig. 7. Dose–response curves of δ-opioid receptor-induced cytosolic Ca2+ elevation after mu
cytosolic Ca2+ elevation after muscarinic receptor stimulation with CCh, in either buffer so
elevation, in either buffer solutions. Data for each concentration are reported as percent of
given 5 min before the δ-opioid receptor selective agonist DPDPE. Data are means±S.E. ofin agreement with the postulated coupling of their receptors to Gi/o
and not with Gs.
3.5. M3 muscarinic and BK2 receptor interaction
In Figs. 2a and 6, we report the results obtained following the
subsequent stimulation of two Gq/11-coupled receptor, i.e. the M3
muscarinic and BK2 receptors. In both buffers, CCh, incubated with
cells at increasing concentrations (1 pM–1 μM) 5 min prior to
bradykinin, decreased the potency and efﬁcacy of the latter com-
pound. At the highest concentration used (1 μM) CCh completely
abolished bradykinin-induced elevation of [Ca2+]i (IC50 values are
shown in Table 2).
3.6. M3 muscarinic and δ-opioid receptor interaction
As reported in literature [15], the prior stimulation of a Gq/11-
coupled receptor, e.g. the M3 muscarinic receptor, caused a marked
increase in the ability of mobilizing intracellular calcium of a Gi/o-
coupled receptor, e.g. the δ-opioid receptor. As shown in Fig. 7a and c,
in both the Ca2+-containing and Ca2+-free buffers, with each given
dose of the muscarinic receptor agonist, CCh, we observed an increase
of DPDPE-induced elevation of [Ca2+]i that was stronger with lower
concentrations of the δ-opioid agonist and absent at its highest
concentrations. With given doses of DPDPE up to 100 nM, thescarinic receptor pre-stimulation. (a and c) Dose–response curves for DPDPE-induced
lutions. (b and d) Dose–response curves of CCh potentiation of DPDPE-induced Ca2+
the maximal effect obtained with CCh 1 mM. The muscarinic receptor agonist CCh was
at least n=6 different determinations.
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being observed at 1 μM (Fig. 7b and d, Table 2).
3.7. M3 muscarinic and CB1 receptor interaction
As shown in Figs. 2b, 8a and c, in both the Ca2+-containing and
Ca2+-free buffers, the pre-stimulation of the M3 muscarinic receptor
with CCh caused amarked enhancement of ACEA-induced elevation of
[Ca2+]i that was stronger with lower concentrations of the CB1 agonist
and absent with its highest concentrations. With given doses of ACEA
up to 100 nM, the stimulatory effect of CCh was dose-dependent, the
maximal effect being observed at 1 μM in both Ca2+-containing and
Ca2+-free buffers (Fig. 8b and d, Table 2).
3.8. CB1 and δ-opioid receptor interaction
As shown in Figs. 2c, 9a and c, in both Ca2+-containing and Ca2+-
free buffers, the consecutive stimulation of CB1 receptors with ACEA
and of the δ-opioid receptors with DPDPE, caused a dose-dependent
potentiation of the effect of the latter on [Ca2+]i. In this case, unlike
the results shown above for the Gq/11–Gi/o-coupled receptor interac-
tions, the effect of ACEA was stronger with higher concentrations of
DPDPE (1 nM–1 μM). Also in this case, however, the effect of the ﬁrst
agonist given to cells increased with its increasing concentrations
(10 nM–1 μM, ACEA). Dose–response curves and EC50 values are
shown in Fig. 9b and d, Table 2.Fig. 8. Dose–response curve of CB1 cannabinoid receptor-induced cytosolic Ca2+ elevation
induced cytosolic Ca2+ elevation aftermuscarinic receptor stimulationwith CCh, in either buf
elevation, in either buffer solutions. Data for each concentration are reported as percent of th
before the CB1 receptor selective agonist ACEA. Data are means±S.E. of at least n=6 differe3.9. Pharmacological characterization of the M3 muscarinic and CB1 or
δ-opioid receptor interaction
Based on the above results, the pharmacological characterization
of both the M3 muscarinic–δ-opioid and M3 muscarinic–CB1 receptor
interactions was performed using CCh at 1 μM and DPDPE and ACEA,
both at 10 nM. In Fig. 10 we show the effects obtained in either Ca2+-
containing or Ca2+-free buffers. The pre-stimulationwith CCh at 1 μM
results in a strong enhancement of both δ-opioid and CB1 receptor-
elevated [Ca2+]i. In particular, in the Ca2+-containing buffer, the
enhancement observed was ∼610% and ∼450% of the value obtained
with the agonists alone, for DPDPE and ACEA, respectively, while in
the Ca2+-free buffer, it was ∼450% for both these agonists. In the
Ca2+-containing buffer, the potentiating effect of CCh was entirely or
almost completely abolished by the muscarinic non-selective antago-
nist, atropine (Atro, 4 μM) and by the M3 muscarinic selective
antagonist, 4-DAMP (10 nM), for both agonists, and by the selective
CB1 antagonist, AM251 (1 μM), for ACEA, and the δ-opioid antagonist
naltrindole (1 μM), for DPDPE. By contrast, the PLCβ inhibitor, U73122,
at a concentration (1 μM) shown above not to affect the effects of the
single administration of ACEA or DPDPE, and to inhibit CCh-induced
Ca2+ mobilization, exerted a slight inhibitory effect in the Ca2+-
containing buffer, and almost completely abolished the potentiation
by CCh in the Ca2+-free buffer. The PC-PLC inhibitor D609, at a
concentration (40 μM) shown above not to affect the effects of the
single administration of ACEA or DPDPE, and to inhibit the effect ofafter muscarinic receptor pre-stimulation. (a and c) Dose–response curves for ACEA-
fer solutions. (b and d) Dose–response curves of CCh potentiation of ACEA-induced Ca2+
e maximal effect obtained with CCh 1 mM. The muscarinic agonist CCh was given 5 min
nt determinations.
Fig. 9. Effect of Gi/o–Gi/o-coupled receptor consecutive stimulation on cytosolic Ca2+ elevation. (a and c) Dose–response curves for DPDPE-induced cytosolic Ca2+ elevation after CB1
receptor stimulationwith ACEA, in either buffer solutions. (b and d) Dose–response curves of ACEA potentiation of DPDPE-induced cytosolic Ca2+ elevation, in either buffer solutions.
Data are expressed as percent of the maximal effect obtained with CCh 1 mM. The selective CB1 agonist ACEA, was given 5 min before the δ-opioid receptor agonist DPDPE. Data are
means±S.E. of at least n=6 different determinations.
1299P. Marini et al. / Biochimica et Biophysica Acta 1793 (2009) 1289–1303CCh alone only in the Ca2+-containing buffer, abolished the potentia-
tion by CCh in both buffers. Thapsigargin (1 μM), which inhibited the
effect of CCh (only in the Ca2+-containing buffer), but not of ACEA or
DPDPE when given alone, was able to reduce the CCh-potentiating
effect on both CB1 and δ-opioid receptors in both buffers. The calcium
channel blockers, lanthanum chloride (La 3+, 1 μM) and niﬁdepine
(Nife, 1 μM), which were without effect on each of the agonists given
per se to cells, were able to reduce the CCh-potentiating effect only in
the Ca2+-containing buffer, without any effect in the Ca2+-free buffer.
The involvement of PKC in the CCh-potentiating effect on both CB1
and δ-opioid receptors was tested by replacing the muscarinic
receptor agonist carbachol with the PKC activator PDbU. In both
Ca2+-containing and Ca2+-free buffers, PDbU (1 μM) increased the
Ca2+ mobilization induced by ACEA (255.45±41.67% and 228.05±
67.79%, respectively). PDbU (1 μM) increased also the Ca2+ mobiliza-
tion induced by DPDPE (273.68±39.14% for Ca2+-containing buffer
and 259.94%±54.46 for Ca2+-free buffer). However, in the Ca2+-
containing buffer, both ACEA and DPDPE actions on Ca2+mobilization
were affected in exactly the same way by the PKC-inactive analogue,
4α-PdbU (255.00±49.49% and 248.63±32.80%, respectively), and
similar results were obtained in the Ca2+-free buffer (282.00±38.10%
for ACEA, 223.73±71.99% for DPDPE), thus indicating that PKC was
not involved in the effects of PDbU. Accordingly, the CCh-potentiating
effect on both CB1 and δ-opioid receptor-mediated calcium mobiliza-
tionwas not signiﬁcantly affected by the PKC inhibitor BIM (0.5 μM) in
both buffers (452.37±43.16% for ACEA and 679.44±90.56% forDPDPE, in the Ca2+-containing buffer, and 439.04±59.34% and
540.53±15.91%, in the Ca2+-free buffer).
In cells pre-incubated with PTX, the CCh-potentiating effects were
all completely abolished in both buffers. Pre-incubation of cells with
CTX, instead, caused a reduction of the CCh-potentiating effects only
in the Ca2+-containing buffer, especially on DPDPE-mediated eleva-
tion of [Ca2+]i. Finally, in both buffers, the effect of CCh on ACEA was
not signiﬁcantly affected by two inhibitors of the biosynthesis of the
endocannabinoid 2-AG, THL and OMDM188 (which act on DAGLal-
pha), nor by an inhibitor of 2-AG enzymatic hydrolysis, OMDM169
(which acts on MAGL), at concentrations previously reported to full
block 2-AG biosynthesis and degradation in neuroblastoma cells,
respectively [19] (Fig. 2, Supplementary materials).
3.10. Pharmacological characterization of the CB1 and δ-opioid receptor
interaction
When cells were pre-stimulated with ACEA 10 nM, the subsequent
stimulation of δ-opioid receptors with DPDPE 100 nM induced a
stronger enhacement of [Ca2+]i than with DPDPE alone (Figs. 2c and
11). In this case, both the non-selective muscarinic antagonist, atro-
pine, and the M3 muscarinic selective antagonist, 4-DAMP, did not
counteract this effect, whereas the PLCβ inhibitor U73122, in presence
of the Ca2+-containing buffer, completely abolished the CB1 potentia-
ting effect on δ-opiod receptor, the effect being less marked in the
Ca2+-free buffer (Fig. 11). By contrast, D609, a PC-PLC inhibitor,
Fig. 10. Pharmacological characterization of the interaction between muscarinic and CB1 or δ-opioid receptors. The effects of the pre-stimulation of muscarinic receptors with CCh
(1 μM) on either CB1 (ACEA,10 nM) or δ-opioid (DPDPE,10 nM) receptor-induced cytosolic Ca2+ elevation, in either buffer solutions, are shown. The effects of themuscarinic receptor
non-selective antagonist, atropine (Atro) and of the selective M3 antagonist 4-DAMP, the PLC inhibitors, U73122 and D609, the SERCA inhibitor, thapsigargin (Thaps), the calcium
channel blockers, lanthanum chloride (La3+) and nifedipine (Nife), and the CB1 and δ-opioid selective antagonists, AM251 and naltrindole (Naltri), respectively, are shown. The
effects of previous cell incubation with PTX and CTX are also shown. Data for each concentration are reported as percent of the effects observed with either agonist (ACEA or DPDPE)
alone. The antagonists/inhibitors were given 5min before the M3muscarinic agonist CCh. Data are means±S.E. of a least n=8measurements. #pb0.05 vs Ctrl ACEA 10 nM OneWay
ANOVA followed by Dunn's test. §pb0.05 vs Ctrl DPDPE 10 nM One Way ANOVA, followed by Dunn's test. ⁎pb0.05 vs CCh 1 μM One Way ANOVA, followed by Dunn's test.
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Ca2+-containing buffer. The SERCA inhibitor, thapsigargin (Thps,
1 μM), was inefﬁcacious in the Ca2+-containing buffer, and exerted
complete inhibition in the Ca2+-free buffer. Both calcium channel
blockers, La3+ (1 μM) and nifedipine (Nife, 1 μM), were able to
completely inhibit the ACEA potentiating effect on δ-opioid receptor-
elevated [Ca2+]i only in the Ca2+-containing buffer. Both the selective
CB1 and δ-opioid receptors antagonists, AM251 (1 μM) and naltrindole
(Naltri, 1 μM), respectively, abolished the ACEA potentiating effect in
both buffers (Figs. 2c, 11).
The PKC inhibitor BIM (0.5 μM) was tested to ascertain the
involvement of PKC in the potentiating effect mediated by CB1
receptor on the δ-opioid receptor-induced calcium mobilization in
both buffers. In the Ca2+-containing buffer, BIM, did not affect the
δ-opioid Ca2+mobilization (439.80±56.91%), whereas in the Ca2+-free buffer a slight, non-statistically signiﬁcant, inhibition was
observed (346.87±36.04%).
Finally, cells pre-incubatedwith PTX and, surprisingly, alsowith CTX,
did not respond any longer to the ACEA potentiating effect on δ-opiod
receptor-mediated calciummobilization in both buffers (Fig. 11).
4. Discussion
Activation of cannabinoid CB1 receptors can be coupled to elevation
of [Ca2+]i [1,5]. One of the aims of the present study was to establish
whether, in a neuronal model, the efﬁcacy of this coupling can be
enhanced by previous stimulation of a Gq/11-coupled receptors, as pre-
viously shown for δ-opioid receptors and M3 muscarinic receptors [15].
Furthermore, we investigated if such interactions occur also between
two Gi/o-coupled receptors, i.e. the CB1 and the δ-opioid receptors.
Fig.11. Pharmacological characterization of the interaction between CB1 and δ-opioid receptors. The effect of the pre-stimulation of CB1 receptors (ACEA,10 nM) on δ-opioid receptor-
mediated elevation of intracellular Ca2+ (DPDPE, 10 nM), in either buffers, are shown. The effects of the muscarinic receptor non-selective antagonist atropine (Atro) and M3-
selective antagonist 4-DAMP, the PLC inhibitors, U73122 and D609, the SERCA inhibitor, thapsigargin (Thaps), the calcium channel blockers, lanthanum chloride (La3+) and
nifedipine (Nife), and the CB1 and δ-opioid selective antagonists, AM251 and naltrindole (Naltri), respectively, are shown. The effects of previous cell incubationwith PTX and CTX are
also shown. Data for each concentration are reported as percent of the effects observed with either agonist (ACEA or DPDPE) alone. The antagonists/inhibitors were given 5 min
before the muscarinic agonist CCh. Data are means±S.E. of a least n=8measurements. °pb0.05 vs ACEA 10 nM (Ca2+-containing buffer) One Way ANOVA followed by Dunn's test.
#pb0.05 vs Ctrl DPDPE 10 nM (Ca2+-containing buffer) One Way ANOVA, followed by Dunn's test. §pb0.05 vs Ctrl DPDPE 10 nM (Ca2+-free buffer) One Way ANOVA, followed by
Dunn's test. ⁎pb0.05 vs ACEA 10 nM (Ca2+-free buffer) One Way ANOVA, followed by Dunn's test.
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neurons used in this study, the human neuroblastoma SH-SY5Y cells,
do express CB1, δ-opioid and M3 muscarinic receptors. These results
were validated by means of western immunoblotting. Next, we
examined the effect of agonists of these three receptors on [Ca2+]i in
these cells. We conﬁrmed the strong effect of muscarinic receptors on
this signaling event by using CCh, and the weak effect of δ-opioid
receptors by using DPDPE [15]. Furthermore, we found that also
activation of CB1 receptors causes elevation of [Ca2+]i both in the
absence and presence of extracellular Ca2+, with the potency
expected from the Ki of the agonist used, but with poor efﬁcacy as
compared to Gq/11-coupled receptor agonists. The pharmacological
tools used conﬁrmed that CCh acted by activating M3 muscarinic
receptors and Gq/11-induced activation of PLC enzymes and subse-
quent mobilization of Ca2+ from the sarcoplasmic reticulum, since its
effect on [Ca2+]i were not inﬂuenced by either PTX or CTX, and were
reduced by inhibitors of the phosphoinositide (PI)-selective PLC
(possibly PLCβ) as well as by the SERCA inhibitor thapsigargin. By
contrast, the weak effects of CB1 and δ-opioid receptors on [Ca2+]i
were due to activation of Gi/o-coupled pathways, as they were
inhibited by PTX, but not to the activation of PI-PLC, indicating that
phosphoinositide-bis-phosphate (PIP2)-independent mobilization of
intracellular Ca2+ plays a role in this small effect. In the cases of all
three receptor types, activation of voltage-activated calcium channels
(VACCs) does not play a role in their elevation of [Ca2+]i in the
presence of extracellular Ca2+, which in the case of CCh was
surprisingly also unaffected by thapsigargin, but became affected by
the PC-PLC inhibitor, D609. This might be due to the occurrence of
ampliﬁcatory cascades involving non-VACC plasma membrane cal-
cium channels and PC-PLC, which might have masked the effect of
thapsigargin.
The ﬁrst original ﬁnding of this study was that prior activation of
M3 muscarinic receptors by CCh caused a striking enhancement of the
effects on [Ca2+]i not only of DPDPE, but also of the CB1-selective
agonist ACEA. These effects: i) were particularly marked with low
concentrations of the two agonists of the Gi/o-coupled receptors, ii)
increased linearly with the concentration of CCh, and iii) weresigniﬁcantly attenuated not only by speciﬁc antagonists of each
receptor, but also by tools that had been ineffective when tested on
each Gi/o-coupled receptor agonist alone. These included VACC
inhibitors, thapsigargin, PLC inhibitors and, to some extent, CTX, in
the presence of extracellular calcium, and thapsigargin and PLC
inhibitors, in its absence. These ﬁndings suggest that activation of M3
muscarinic receptors by CCh causes a dramatic upward shift in the
sensitivity of the elevation of [Ca2+]i to CB1 and δ-opioid receptor
agonists. This shift might be due to the formation of higher afﬁnity
binding sites for ACEA and DPDPE, respectively, in these receptors, and
to the stronger coupling of the latter to [Ca2+]i-mobilizing/elevating
effector systems (e.g. PLCs and VACCs), mediated, in part, also by α-
subunits of different G-proteins, e.g. the CTX-sensitive αs, which have
been reported to enhance [Ca2+]i directly or indirectly (i.e. via cAMP
elevation) [8,21,22]. In particular, a shift towards PLC-mediated and
PTX- and thapsigargin-sensitive pathways for intracellular Ca2+
mobilization from the sarcoplasmic reticulum, possibly of the same
type as those observed for CB1 in other cells [5,21], was observed in
the absence of extracellular calcium. Importantly, the potentiation by
CCh of the effects of DPDPE and ACEA decreased with increasing nM
concentrations of the two agonists. This might suggest that the two
putative mechanisms for [Ca2+]i elevation, one sensitive to sub-nM/
low-nM, and the other to high nM, concentrations of ACEA or DPDPE,
might co-exist and overlap, thus yielding an overall measurable effect
on [Ca2+]i that is the average of those obtained with each mechanism
alone. Whatever the underlying mechanism, the ﬁnding of a
muscarinic–CB1 interaction at the level [Ca2+]i, if extended also to
M2 receptors, might be relevant to the previously reported inhibitory
effects of these and CB1 receptors on GABA release from hippocampal
inhibitory neurons [23]. Furthermore, given the previously described
localization of both [Ca2+]i-coupled CB1 receptors [24] and M3
receptors [25] in astrocytes, such interaction might also inﬂuence
the endocannabinoid-mediated neuron–astrocyte communication
mechanisms recently described in the hippocampus [24].
We also report here that, while two Gq/11-coupled receptors,
such as BK2 and muscarinic receptors, occlude each other in their
effects on [Ca2+]i, possibly because they converge on the same pool of
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cellular calcium, two Gi/o-coupled receptors can reinforce each other
on Ca2+. In fact, CB1 receptor stimulation with ACEA strongly
enhanced the effect on [Ca2+]i of δ-opioid receptors. The nature of
this interaction is probably different from that depicted above for
muscarinic and Gi/o-coupled receptors. In fact, this reinforcement
clearly relies on VACCs and both Gi/o and Gs-coupled pathways, in the
presence of extracellular calcium, and on PLC, the sarcoplasmic
reticulum and Gi/o and Gs-coupled pathways, in its absence. Further-
more, since the effect was not observed with low DPDPE concentra-
tions and increased with increasing concentrations of ACEA, it is
possible to suggest that this interaction is not due to a change in the
sensitivity of the δ-opioid receptor to its agonist, but rather to the
increase of the efﬁcacy of its coupling to elevation of [Ca2+]i, which
entirely replaces the “original” coupling of the receptor to this signal,
observed in the absence of ACEA.
Based on the different pharmacological proﬁle of the two effects
described here, it is possible to speculate on their possible molecular
nature. Regarding the sensitising effect of muscarinic on Gi/o-coupled
receptors, of the agents that affected the effects of ACEA and DPDPE in
the presence of CCh, apart from atropine and 4-DAMP, only U73122
also affected the effect of CCh per se on [Ca2+]i in both the presence
and absence of extracellular Ca2+. Since this compound inhibits
PI-PLC, one might hypothesize that PI-PLC-derived messengers cause
a post-translational modiﬁcation of CB1 and δ-opioid receptors,
responsible for their higher sensitivity to the respective agonists as
well as for their higher efﬁcacy at elevating [Ca2+]i. This higher
efﬁcacy might be due, in part, to activation of CTX and/or PTX-
sensitive G-proteins and thapsigargin-sensitive calcium stores, or to
the coupling to VACCs, mechanisms that are not involved in the effects
of CB1 and δ-opioid receptor agonists alone. Since we found no
evidence for PKC (and, hence, diacylglycerol) involvement, such post-
translational receptor modiﬁcation might be triggered by calcium-
dependent protein kinases via elevation of [Ca2+]i caused by CCh.
Since heterodimers between CB1 and Gq/11 coupled receptors have
been described [26], it is possible that pre-treatment of cells with CCh
causes CB1-M3 heterodimerization and subsequent sensitisation of
CB1-coupling to elevated [Ca2+]i. Given that CB1 receptors can form
heterodimers also with Gi/o-coupled receptors [27–28], a similar
mechanism might also underlie in part the potentiation by CB1 of δ-
opioid receptor coupling to [Ca2+]i. Finally, the possibility that CCh
potentiates the effect of ACEA by stimulating the biosynthesis of 2-AG
[29], as recently shown for the angiotensin AT1 receptor [30], is
unlikely based on our present experiments with agents that selec-
tively manipulate 2-AG levels.
In conclusion, we have described here for the ﬁrst time that M3
muscarinic receptor activation dramatically sensitizes CB1 receptors to
their coupling to elevation of [Ca2+]i in neuronal cells, and that CB1
receptors, in turn, elevate the efﬁcacy of δ-opioid receptor coup-ling to
this intracellular signal. These interactions may have several implica-
tions, given the numerous reports of muscarinic–CB1 receptor cross-
talk during retrograde signaling [29], and the previous evidence
suggesting that CB1 and δ-opioid agonists synergize at inhibiting pain
[20,31–34]. Speciﬁc studies are now required in order to understand
the nature of the interactions described in this study.
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